Ribosome-inactivating protein MAP30 isolated from Momordica charantia L. induces apoptosis in hepatocellular carcinoma cells.

Abstract

BACKGROUND:

Ribosome-inactivating proteins (RIPs) have been reported to exert anti-tumor and anti-virus activities. A recent patent CN202011568116.7 has developed a new method to prepare Momordica anti-HIV protein of 30 kDa (MAP30). MAP30 is a type I RIP, which kills various tumor cells through the N-glycosidase activity and irreversibly inhibits protein synthesis.

OBJECTIVE:

To assess the potential role of MAP30 in inducing apoptosis of human hepatocellular carcinoma HCC-LM3 cells and elucidate the molecular mechanism of MAP30.

METHODS:

CC-8 assay was used to assess the proliferation of HCC-LM3 cells. Flow cytometry was used to measure the cycle, the level of ROS and apoptosis in HCC-LM3 cells. Western blots were used to measure protein levels Results: Treatment with MAP30 reduced survival and proliferation of human liver cancer HCC-LM3 cells in a dose-dependent manner. PI staining showed cell cycle arrest in G0/G1 phase. Furthermore, MAP30 increased the level of ROS in HCC-LM3 cells in 24 h treatment. To further confirm the role of MAP30 in inducing cell apoptosis, immunoblotting was carried out to detect the change of apoptosis-related proteins including PARP poly (ADP-ribose) polymerase (PARP-1), Casepase3 and Cleaved-Caspase9. We found that PARP-1 and Caspase-3 were downregulated, whereas Cleaved-Caspase9 were up-regulated in HCC-LM3 cells treated with MAP30.

CONCLUSION:

This study indicated that MAP30 has the potential to be a novel therapeutic agent for human hepatocellular carcinoma.

• Authors: Yiping Zhou, Di Yang, Zihao Qiang, Yanfa Meng, Ruigang Li, Xiang Fan, Wei Zhao, Yao Meng
• Journal: Recent patents on anti-cancer drug discovery (Recent Pat Anticancer Drug Discov) (Nov 03 2022) ISSN: 2212-3970 [Electronic] United Arab Emirates
• PMID: 36330636 (Publication Type: Journal Article)
• Copyright: Copyright© Bentham Science Publishers; For any queries, please email at [email protected].